full report link
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif disclosur import disclosur pleas go www wolferesearch com/disclosur
write us wolf research llc lexington avenu suit new york ny
summari rate price target
factset wolf research estim analysi price
companyratingpric pt multipl epsu/d price u/d rel group astrazeneca azn squibb nv novn vx opchf rhhbi rog vx ppchf sni sasi pa pp average average return vs wr global macro outlook
summari view group modestli attract base total sharehold return well-appreci
fundament mix valuat modestli histor averag summer ralli
posit side
 product slowli trend aggreg
neg side
despit better still plenti compani whose pipelin thin spend
also mani big compani chase often smaller target opportun
drug price remain spotlight market access hurdl increas mani new launch
respons challeng drug compani
cut cost match lower revenu
reli help fill gap
narrow focu divest occasion swap asset
wolf research estim analysi
wr global major theme
io never-end sourc import news select exampl includ
first adjuv studi tnbc data data appar great timelin push
azn roxadustat anemia calquenc vs imbruvica cll
gsk bcma multipl myeloma prima tsro parp
abrocitinib atop dermat rivipansel sickl cell diseas
smaller chang unlik watersh moment presidenti cycl promis
keep topic spotlight medicar
commerci level continu squeez variou therapeut area
 tax reform lower valuat target compani deal final happen
bolt-on sub remain common big deal rare period happen
one impedi lack bigger target good fundament
compani report wolf research analysi
wr global rel valuat return
global pharma trade modestli
big move summer give
back recent
wolf research estim analysi price-to-earnings calcul base
compani report wolf research estim analysi
view view view reveneu growth ep growth ep growth reveneu growth ep growth revenu growth base revenu analysi view differ view
window base revenu
window base revenu
growth profil across window base revenu
 exclud futur pipelin drug
show compani biggest futur loss navig
compani report wolf research estim analysi
bristol-my squibb op celg hmmm cheap ignor
unlov stock controversi rate io misstep hurt manag credibl
view still valu io dont like celg per se upsid downsid
still ahead import uncertain io binari event low valuat alreadi discount much
us lung like fail howev chemo combo lung like work keep relev
like io name sit front lt option adjuv usag ex-u opportun gen agent
possibl interlop come celg deal closesbut low odd
valuat super low impli price-to-earnings pro-forma put lower excess
long-term trajectori opdivo mani variabl limit lung read-out
celg deal cover problem opdivo convers defens move management thwart bid
bmi celg deliv high growth heavi loe exposur
gutter sinc celg deal keep gutter
think valuat low despit genuin controversi still small chanc overbid
less clear time tell burden proof show lt patent cliff manag
wolf research estim analysi
astrazeneca op best long-term ep grower must stock
gener well-lik bear still issu extern
best lt ep grower group averag importantli come base already-approv product
margin expans stori structur heavili out-of-whack today normal base grow
heavi exposur oncolog hot diseas area today second
heavi exposur china total sale peer average grow double-digit relev portfolio product
extern well-known neg dont tri justifi either accept dont
valuat among highest group tie
potenti concern consensu model much margin expans
move higher reflect scarciti larg high-growth biopharma name
ye stock inflect point growth final return big uncertain binari event
ye must stock best grower coverag
wolf research estim analysi
merck op keytruda growth reason valuat
consensu buy variou io win keytruda gardasil lynparza
done fantast job io like sit front lt option adjuv usag ex-u opportun
gardasil stori better understood still substanti under-model consensu low
see report link
one doubl digit ep grower
valuat fair rel growth low event risk
keytruda driver seat io topsy-turvi world could unseat
pipelin thin solut larger tie-up larg pharma expressli off-the-t
ever get rid anim health probabl long grow faster pharma
januvia loe flatten ep year
analyst day june first long time
ye valuat still reason growth deliv
ye reason short term januvia loe paus growth trajectori
wolf research estim analysi
sentiment warm last
view stabl stori slowli execut rebuild credibl growth great
good compani w/one fullest pipelin siponimod other
alcon chapter close perform improv spin come
patent cliff kick road assum gilenya gener get delay
unfortun long-term growth great sap new product strength
va cost cutter promis margin expans might allud big cost cut program someth
achiev predecessor ceo
upcom read-out entresto paragon-hf free call option upsid
upcom event approv perhap importantli price
posit view coincid va take ceo
ye growth catalyst ahead keep investor engag
reason long-term outlook steadi even modest growth
wolf research estim analysi
bifurc view among investor still support mani increasingli loath
growth next decent steep earli eu eros leav question blood cancer busi driver
ep diverg vs consensu op margin unwind biosimilar humira under-model
pipelin numer full me-too product crowd categori
net despit low valuat decent ep cant get past biosimilar humira much uncertainti
humira biosimilar story-kil impact difficult predict acut chronic overhang
hidden downsid on-going enbrel litig could lead earli us gener
pipelin jak realli bundl humira rebat structur chang us
jak high dose dead come time announc high dose xeljanz safeti rais jak risk profil
 go big manag say near-term seem inevit long-term
increasingli nervou earli eu biosimilar experi
dead money could boost stock depend target co
someth dramat happen reshap compani posit
wolf research estim analysi
pp solid grower increment posit
view compani mayb paus strong ralli
guidanc accur weather headwind cialis/forteo better initi expect
trulic major driver higher forecast class scientif sound headi growth ahead
 track record import read out
ultim lt option upsid alzheim diseas nt noth realli stock moment
diabet competit categori sale risk three bucket
price could impact humalog basaglar oral agent class larg interchang
competit mainli oral sema novo
tirzepatid lot faith put behind shorter trial biolog well understood anti-drug antibodi high
event rewind trulic data tanezumab safeti seem iffi tirzepatid dose titrat armo
alreadi high big pendulum swing year ago
tempt hope pullback
ye given lt growth profil matter entri point time
wolf research estim analysi
glaxosmithklin pp shake thing increment posit
stock alreadi bounc dark day div risk fear wait see stori
view definit shake thing structur urgenc buy
lot chang new manag variou level tsro consum jv format eventu spin
attract sotp impli multipl pharma low
ep growth neg advair gx tsro deal stock coverag profil
dividend yield better peer group averag
valuat low end help put floor
three sourc hiv uncertainti competit impact protect drug class chang tsempano
histor weak fixabl new head live far away balanc sheet constrain
shingrix suppli limit quickli cut growth consensu model right
data read-out bcma data tsro prima studi xejula parp
mix point view gener remain lowish
yield-focus might attract
patient value-ori investor mayb ye ripe enough everyon els
wolf research estim analysi
roch pp tug-of-war pipelin biosimilar risk
mix perspect skew posit recent market will look past biosimilar exposur
view like biosimilar haunt stori
arguabl best compani coverag late-stag pipelin realli full
howev sit front end biosimilar exposur
despit big pipelin model lowest ep growth group consensu
clear hoffman-oeri famili incent fulli align extern sharehold focu may
dividend share price dont sell share
model biosimilar eros earli ex-u preced worrisom us variou stakehold
seek way acceler uptak seem destin gain traction think recent medicar advantag chang
pipelin ever big enough overcom biosimilar risk answer possibl
event uncertain time potenti import biosimilar litig initi run
background could lead materi delay herceptin avastin us say much
pipelin news huntington etrolizumab polatuzumab data earli bispecif mab
reason want play nearer-term pipelin option valuat seem high low ep compound-annual-growth-rate
perhap given core abil assess balanc pipelin vs biosimilar continu
wolf research estim analysi
pp pipelin hard move mountain
reason well like valuat rare never stretch
view okay outlook pipelin catalyst ahead
bad ep flat improv thereaft weak histor reli period big
new ceo albert bourla like stay cours exec cte
bore transform deal tabl split remov potenti catalyst
ibranc slow least us uncertainti whether adjuv save day
data read-out tanezumab safeti w/lli seem iffi rivipansel sickl cell atop derm
limit downsid given valuat flattish ep hard see out-performance
think better lt idea
wolf research estim analysi
sanofi pp lower expect name upsid case elus
whole lot go enter stabl period
ep growth return group averag level lt
 weak late-stag pipelin thin good new head fix
lantus/toujeo often describ investor stabilizinghmmm collect sell eur annual
valuat low isnt alway like
new cfo automot industri track record cut cost final happen
dupix acceler ahead due broader atop derm roll-out asthma approv
off-set oral jak competitor come data
 probabl small stuff spend war chest alreadi
bioverativ durabl asset given hemlibra gene therapi competit
investor meet june expect head john reed roch describ vision futur
remain lowish hope cost cut put ice recent
cheap hard see drive upsid case
perhap believ mean revers
wolf research estim analysi
azn w/o europ healthcar compani comparison cover pharma pp peer peform under-perform op outperformsourc factset wolf researchtim anderson md target multipl disclosur
